Trial Profile
A retrospective observational study evaluating weight and BMI changes in aviremic HIV-infected patients who switched to an elvitegravir- or dolutegravir-containing regimen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 18 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018